Urokinase

Base Information

• Chemical Name: Urokinase
• CAS No.: 9039-53-6
• Molecular Formula: Unspecified
• Molecular Weight: 0
• Hs Code.: 3507909090
• Mol file: 9039-53-6.mol

Synonyms:Abbokinase;Actosolv;Breokinase;Double-chainurokinase-type plasminogen activator;E.C. 3.4.21.31;E.C. 3.4.21.73;E.C.3.4.99.26;Persolv;Plasminokinase, urinary;Pro-HGF convertase;Pro-hepatocytegrowth factor convertase;Purochin;Two-chain urokinase;Two-chainurokinase-type plasminogen activator;Ukidan;Urokinase;Urokinase plasminogenactivator;Urokinase-like plasminogen activator;Urokinase-type plasminogenactivator;Uronase;Win 22005;Win-Kinase;

Chemical Property of Urokinase

Chemical Property:

• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: 2-8°C
• Solubility.: Soluble in water.
• Water Solubility.: Reconstitute in water at 100µg/ml

Purity/Quality:

99% ^*data from raw suppliers

Urokinase Plasminogen Activator ^*data from reagent suppliers

Safty Information:

• Pictogram(s): B
• Hazard Codes: B

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Description: Urokinase is an enzyme that is extracted from human urine or kidney cells, which directly cleaves specific peptide bonds, in particular the Arg-560–Val-561 bond in the plasminogen molecule, thus transforming it into plasmin.
• Uses: Plasminogen activator; fibrinolytic; enzyme. It is used for the same indications as streptokinase. The effect of systemic administration of urokinase is unclear. One study reported the effectiveness of superselective ophthalmic artery fibrinolytic therapy of urokinase for CRVO. Urokinase was infused through a microcatheter into the ostium of the ophthalmic artery via the femoral artery. Six eyes of 26 patients had a significant improvement in VA 24 hours after the fibrinolysis; eyes with combined central retinal artery occlusion and CRVO with recent visual impairment appeared to be the most responsive.
• Clinical Use: Fibrinolytic agent: Thrombosed arteriovenous shunts and intravenous cannulas Treatment of thromboembolic occlusive vascular disease, e.g. DVT, PE, peripheral vascular occlusion
• Drug interactions: Potentially hazardous interactions with other drugs None known